Novartis Opens Cell and Gene Therapy Plant in Switzerland

GALWAY, IRELAND--December 11, 2019--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Novartis International AG (NYSE:NVS) (Basel, Switzerland) has inaugurated a new $90 million pharmaceutical plant in Stein, Switzerland, that will focus on gene and cell therapies. Within this article: Details new plant opening, investment, gene and cell therapies focus, potential site for future Kymriah manufacture